Rubius Therapeutics Inc RUBY

NAS: RUBY | ISIN: US78116T1034   29/12/2023
0,057 USD (+2,70%)
(+2,70%)   29/12/2023

19 juli 2022 · HotSpot Therapeutics Appoints Jose Carmona to Board of Directors · Persbericht

28 februari 2022 · Alltrna Appoints Rare Disease Clinical Research Expert, Dr. Anne Pariser, as Vice President, Medical and Regulatory Affairs · Persbericht

15 februari 2022 · Invaio Sciences Strengthens Its Board Of Directors With The Appointment Of Hugh Grant · Persbericht

13 oktober 2021 · Invaio Sciences Secures $50 Million Debt Financing to Develop and Commercialize Agricultural Solutions to Address Climate Change · Persbericht

15 juni 2021 · Dr. Stephen Hahn, 24th US FDA Commissioner and Former Chief Medical Executive at MD Anderson, joins Flagship Pioneering as Chief Medical Officer of Flagship's Preemptive Medicine and Health Security Initiative · Persbericht

25 mei 2021 · Invaio Sciences Raises $88.9 Million to Accelerate the Transition to Biological Agriculture · Persbericht

19 mei 2021 · Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening · Persbericht

30 maart 2021 · Invaio Sciences Strengthens Leadership Team with Appointment of Peleg Chevion as President and Chief Commercial Officer · Persbericht

17 maart 2021 · Rubius Therapeutics Prices Upsized Public Offering of Common Stock · Persbericht

15 maart 2021 · Rubius Therapeutics Announces Proposed Public Offering of Common Stock · Persbericht

15 maart 2021 · Rubius Therapeutics Reports Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors, Demonstrating Single-Agent Activity · Persbericht

12 maart 2021 · Rubius Therapeutics Announces Webcast to Review Initial Clinical Data from Ongoing Phase 1/2 Trial of RTX-240 in Patients with Advanced Solid Tumors · Persbericht

10 maart 2021 · Rubius Therapeutics to Present Initial Clinical Results from the Ongoing Phase 1/2 Clinical Trial of RTX-240 in Advanced Solid Tumors at the American Association of Cancer Research Virtual Annual Meeting · Persbericht

25 februari 2021 · Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at the Level of the Cell as Opposed to a Single Molecular Target · Persbericht

3 februari 2021 · Rubius Therapeutics to Participate in Guggenheim Healthcare Talks | 2021 Oncology Days · Persbericht

4 januari 2021 · Rubius Therapeutics to Present at the Virtual 39th Annual J.P. Morgan Healthcare Conference · Persbericht

Mijn selecties